AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30200089 — intervention group
Group type: EXPERIMENTAL
Intervention: UEScope videolaryngoscope
Number of subjects: 85
Study 30200089 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 85
Study 27563883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT) - 1 mg/day of estradiol valerate plus 5 mg/10 day of medroxiprogesterone
Number of subjects: 100
Study 27563883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24499510 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdrop insemination
Number of subjects: 0
Study 24499510 — intervention group
Group type: COMPARATOR
Intervention: Open insemination
Number of subjects: 0
Study 23917935 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine hygiene with toothbrushing
Number of subjects: 52
Study 23917935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (gel with the same color and consistency and toothbrushing)
Number of subjects: 52
Study 19918203 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily for 12 months)
Number of subjects: 213
Study 19918203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 18276619 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 18276619 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 0
Study 18276619 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Xa levels > 0.9 IU/mL
Number of subjects: 0
Study 18276619 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Clotting Time (ACT) > 325 s
Number of subjects: 0
Study 18276619 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Clotting Time (ACT) < 325 s
Number of subjects: 0
Study 18276619 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Xa levels and covariate-adjusted incidence of death, myocardial infarction, or revascularization
Number of subjects: 0
Study 15819677 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect hemagglutination test (IHA)
Number of subjects: 400
Study 15819677 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of two tests used in parallel (IHA plus ELISA or IHA plus IFA)
Number of subjects: 400
Study 15819677 — intervention group
Group type: COMPARATOR
Intervention: Single IHA testing
Number of subjects: 400
Study 15819677 — intervention group
Group type: COMPARATOR
Intervention: Single ELISA or single IFA testing
Number of subjects: 400
Study 14623061 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 121
Study 14623061 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg tibolone
Number of subjects: 121
Study 14623061 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol plus 1 mg norethindrone acetate
Number of subjects: 121
Study 14623061 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of leptin levels
Number of subjects: 121
Study 14623061 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum leptin
Number of subjects: 121
Study 14623061 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for BMI and fat mass
Number of subjects: 121
Study 11003744 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activating factor antagonist (low-dose 10 mg or high-dose 100 mg)
Number of subjects: 150
Study 11003744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 11003744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal thoracic artery grafting
Number of subjects: 150
Study 11003744 — intervention group
Group type: EXPERIMENTAL
Intervention: Single internal thoracic artery grafting
Number of subjects: 150
Study 11003744 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary endarterectomy
Number of subjects: 150
Study 8977781 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm lignocaine (37 degrees C)
Number of subjects: 60
Study 8977781 — intervention group
Group type: COMPARATOR
Intervention: Cold lignocaine (room temperature)
Number of subjects: 60
Study 1443350 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg/day for 10 days)
Number of subjects: 49
Study 1443350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study 6536515 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (Hypnovel, Roche)
Number of subjects: 40
Study 6536515 — intervention group
Group type: COMPARATOR
Intervention: Diazepam in propylene glycol (Valium, Roche)
Number of subjects: 40
Study 6536515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Midazolam and Diazepam)
Number of subjects: 40
Study 3108780 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device
Number of subjects: 20
Study 3108780 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 20
Study 31126845 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus evofosfamide
Number of subjects: 209
Study 31126845 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 209
Study 29650408 — intervention group
Group type: EXPERIMENTAL
Intervention: OCS Lung device
Number of subjects: 370
Study 29650408 — intervention group
Group type: COMPARATOR
Intervention: Cold storage at 4°C (control)
Number of subjects: 370
Study 27617742 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker (LHW) intervention with reminder calls and resource list
Number of subjects: 600
Study 27617742 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only a list of resources by mail
Number of subjects: 600
Study 23650913 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic injection sclerotherapy (EIS)
Number of subjects: 27
Study 23650913 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed conservatively)
Number of subjects: 27
Study 22721975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile biofeedback training
Number of subjects: 20
Study 22721975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 20
Study 20507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (250 mg) every 12 hours for 6 months
Number of subjects: 32
Study 20507401 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours for 6 months
Number of subjects: 32
Study 18778135 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted motivational interviewing (AMI) group (1 individual AMI session + self-help handbook)
Number of subjects: 108
Study 18778135 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted motivational interviewing (AMI) group
Number of subjects: 108
Study 18778135 — intervention group
Group type: COMPARATOR
Intervention: Control group (handbook only)
Number of subjects: 108
Study 18778135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AMI and control)
Number of subjects: 108
Study 15721701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome
Number of subjects: 9
Study 15721701 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 9
Study 15000443 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood beta‐HBA monitoring (group 1)
Number of subjects: 33
Study 15000443 — intervention group
Group type: COMPARATOR
Intervention: Urine ketone bodies monitoring (group 2)
Number of subjects: 33
Study 10733017 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin 3.75 mg (n=33)
Number of subjects: 56
Study 10733017 — intervention group
Group type: COMPARATOR
Intervention: Lynestrenol 5 mg (n=23)
Number of subjects: 56
Study 8817830 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum circumsporozoite protein vaccine
Number of subjects: 76
Study 8817830 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (control)
Number of subjects: 76
Study 1306086 — intervention group
Group type: EXPERIMENTAL
Intervention: Diapulse therapy (pulsed electromagnetic energy of 27.12 MHz frequency)
Number of subjects: 0
Study 3908316 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 32
Study 3908316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29953338 — intervention group
Group type: COMPARATOR
Intervention: ClinPro XT Varnish (XTV)
Number of subjects: 55
Study 29953338 — intervention group
Group type: COMPARATOR
Intervention: Duraphat (DUR)
Number of subjects: 55
Study 29953338 — intervention group
Group type: COMPARATOR
Intervention: Desensibilize Nano P (NP)
Number of subjects: 55
Study 29953338 — intervention group
Group type: COMPARATOR
Intervention: ClinPro White Varnish (CWV)
Number of subjects: 55
Study 29953338 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 55
Study 29146277 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering LDL cholesterol with simvastatin/ezetimibe
Number of subjects: 0
Study 29146277 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline CRP
Number of subjects: 0
Study 29146277 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline LDL cholesterol
Number of subjects: 0
Study 27825007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dose-dense chemotherapy (4 cycles of leukocyte nadir-based tailored and dose-dense epirubicin and cyclophosphamide every 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks)
Number of subjects: 2017
Study 27825007 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-weekly chemotherapy (3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3 cycles of docetaxel every 3 weeks)
Number of subjects: 2017
Study 27825007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored dose-dense chemotherapy
Number of subjects: 2017
Study 27825007 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-weekly chemotherapy
Number of subjects: 2017
Study 24423358 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH-suppressive L-T4 doses
Number of subjects: 79
Study 24423358 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement L-T4 doses
Number of subjects: 79
Study 24423358 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 79
Study 21681818 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based memory training
Number of subjects: 44
Study 21681818 — intervention group
Group type: COMPARATOR
Intervention: Therapist-led memory training
Number of subjects: 44
Study 20686332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactomax (1.5 g)
Number of subjects: 8
Study 17908630 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 17908630 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0
Study 16109568 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone urinary catheters
Number of subjects: 60
Study 16109568 — intervention group
Group type: COMPARATOR
Intervention: Latex urinary catheters
Number of subjects: 60
Study 12426862 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin, doxazosin, tamsulosin, terazosin (α1‐adrenoceptor antagonists)
Number of subjects: 0
Study 12426862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dosing regimen of α1‐adrenoceptor antagonists
Number of subjects: 0
Study 11015162 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 1200 mg once weekly (n = 321)
Number of subjects: 643
Study 11015162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 322)
Number of subjects: 643
Study 11015162 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 643
Study 11015162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 9001826 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-microgram/d estradiol
Number of subjects: 273
Study 9001826 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-microgram/d estradiol
Number of subjects: 273
Study 9001826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 1360557 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily + sotalol
Number of subjects: 2035
Study 1360557 — intervention group
Group type: COMPARATOR
Intervention: Placebo + sotalol
Number of subjects: 2035
Study 2865914 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (50 μg)
Number of subjects: 30
Study 30820995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram predicting IHA
Number of subjects: 379
Study 29723754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense hierarchical figures
Number of subjects: 1
Study 29723754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse hierarchical figures
Number of subjects: 1
Study 28700587 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory community and health system intervention (client service charter and quality-improvement process)
Number of subjects: 2085
Study 28700587 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory community and health system intervention
Number of subjects: 2085
Study 26828335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional nursing form intervention coordinated by nurses after attending ad hoc teaching sessions
Number of subjects: 0
Study 23269114 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen screening
Number of subjects: 0
Study 23269114 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapolated ERSPC results
Number of subjects: 0
Study 23269114 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected cases in the US
Number of subjects: 0
Study 23269114 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC results
Number of subjects: 0
Study 23269114 — intervention group
Group type: COMPARATOR
Intervention: Control arm screening in PLCO trial
Number of subjects: 0
Study 21569044 — intervention group
Group type: EXPERIMENTAL
Intervention: S-303 treated RBCs
Number of subjects: 27
Study 21569044 — intervention group
Group type: COMPARATOR
Intervention: Control RBCs
Number of subjects: 27
Study 18093108 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality circles with traditional anonymous feedback
Number of subjects: 256
Study 18093108 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality circles with open benchmark
Number of subjects: 256
Study 18093108 — intervention group
Group type: EXPERIMENTAL
Intervention: High medication guideline adherence
Number of subjects: 256
Study 18093108 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of theophylline
Number of subjects: 256
Study 16239318 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu‐Met plus oral contraceptive
Number of subjects: 31
Study 16239318 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu‐Met plus transdermal contraceptive
Number of subjects: 31
Study 12672915 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg (640 mg/d additional dietary cholesterol)
Number of subjects: 40
Study 12672915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/d additional dietary cholesterol)
Number of subjects: 40
Study 10751252 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure to S. pyogenes exotoxins
Number of subjects: 0
Study 10751252 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR expression analysis of CD8+ MBP-reactive T cells
Number of subjects: 0
Study 10751252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine mRNA quantification of mononuclear cells
Number of subjects: 0
Study 9394653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 25
Study 9394653 — intervention group
Group type: COMPARATOR
Intervention: Spiral CT
Number of subjects: 25
Study 8378157 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Dental Anesthesia (EDA)
Number of subjects: 27
Study 8378157 — intervention group
Group type: COMPARATOR
Intervention: Traditional Local Anesthesia
Number of subjects: 27
Study 3946247 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (10 or 20 mg daily) and hydrochlorothiazide (50 mg daily)
Number of subjects: 34
Study 30497467 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone Maintenance Treatment Programme (MMTP)
Number of subjects: 17
Study 30497467 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sectorial approach to managing OUD
Number of subjects: 17
Study 30497467 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limit enforcement on client engagement
Number of subjects: 17
Study 26731696 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 800 mg/day for 10 days
Number of subjects: 80
Study 26731696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23666018 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) - cycling tailored to expend 400 kcal
Number of subjects: 0
Study 23666018 — intervention group
Group type: COMPARATOR
Intervention: Control condition - time-matched no exercise
Number of subjects: 0
Study 23666018 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 0
Study 24370797 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic root venting (Group I)
Number of subjects: 301
Study 24370797 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary arterial venting (Group II)
Number of subjects: 301
Study 24370797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery venting
Number of subjects: 301
Study 20942646 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7128 monotherapy for 2 weeks (1500 mg twice daily)
Number of subjects: 117
Study 20942646 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7128 in combination with SOC for 4 weeks (1000 mg and 1500 mg twice daily)
Number of subjects: 117
Study 20942646 — intervention group
Group type: COMPARATOR
Intervention: Control group (SOC only)
Number of subjects: 117
Study 18806709 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (PBs) administration
Number of subjects: 0
Study 18806709 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 16784998 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR+AED
Number of subjects: 20396
Study 16784998 — intervention group
Group type: COMPARATOR
Intervention: CPR alone
Number of subjects: 20396
Study 14558182 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication advice and reviews by specialists in clinical pharmacology and cardiology.
Number of subjects: 80
Study 14558182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 80
Study 10906167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrology service (n = 114)
Number of subjects: 161
Study 10906167 — intervention group
Group type: COMPARATOR
Intervention: Internal medicine service (n = 105)
Number of subjects: 161
Study 10906167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrology service
Number of subjects: 161
Study 10906167 — intervention group
Group type: COMPARATOR
Intervention: Internal medicine service
Number of subjects: 161
Study 8813265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured autologous epithelial autografts
Number of subjects: 22
Study 8813265 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard burn wound coverage)
Number of subjects: 22
Study 7925067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar (Hoffman-LaRoche)
Number of subjects: 2
Study 7925067 — intervention group
Group type: EXPERIMENTAL
Intervention: Falcidin (Cosmos)
Number of subjects: 2
Study 2899439 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (400 mg)
Number of subjects: 16
Study 2899439 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg)
Number of subjects: 16
Study 31126278 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTI-BREAK intervention (3 x 5-minute moderate-intensity breaks daily)
Number of subjects: 374
Study 31126278 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTI-BREAK intervention
Number of subjects: 374
Study 28409771 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cataract surgery (within the first week after trauma)
Number of subjects: 60
Study 28409771 — intervention group
Group type: COMPARATOR
Intervention: Late cataract surgery (from the first to second month after trauma)
Number of subjects: 60
Study 28409771 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cataract surgery
Number of subjects: 60
Study 28409771 — intervention group
Group type: COMPARATOR
Intervention: Late cataract surgery
Number of subjects: 60
Study 25834589 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide lining paste (Dycal) - Control group A
Number of subjects: 8
Study 25834589 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA (standard double‐visit method) - Group B
Number of subjects: 8
Study 25834589 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA (single‐visit method) - Group C
Number of subjects: 8
Study 25834589 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide injectable paste (Multi‐Cal) - Group D
Number of subjects: 8
Study 23306175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography-guided supine PCNL (group A)
Number of subjects: 92
Study 23306175 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoroscopic-guided prone PCNL (group B)
Number of subjects: 92
Study 20632097 — intervention group
Group type: EXPERIMENTAL
Intervention: Live View Video Capsule Endoscopy (VCE)
Number of subjects: 24
Study 20632097 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical assessment (Control)
Number of subjects: 24
Study 19056590 — intervention group
Group type: COMPARATOR
Intervention: 0 g whole egg protein
Number of subjects: 6
Study 19056590 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g whole egg protein
Number of subjects: 6
Study 19056590 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g whole egg protein
Number of subjects: 6
Study 19056590 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g whole egg protein
Number of subjects: 6
Study 19056590 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g whole egg protein
Number of subjects: 6
Study 17174630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus stents
Number of subjects: 205
Study 17174630 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel stents
Number of subjects: 205
Study 15150632 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-brushing (NB) side
Number of subjects: 12